Prevalence and risk factors of high echocardiographic probability of pulmonary hypertension in myeloproliferative neoplasms patients.
Yanika JindamaiEkarat RattaritamrongArintaya PhrommintikulLalita YongsmithPokpong PiriyakhuntornThanawat RattanathammetheeSasinee HantrakoolChatree Chai-AdisaksophaAdisak TantiworawitLalita NorasetthadaPublished in: International journal of hematology (2020)
Pulmonary hypertension (PH) is emerging as a complication of myeloproliferative neoplasms (MPNs). This was a prospective study conducted at Chiang Mai University Hospital. The primary objective was to determine the prevalence of high echocardiographic probability of PH in MPNs patients. The secondary objectives were to determine risk factors of PH and the correlation between risk factors and peak tricuspid regurgitation velocity (TRVmax). All MPNs patients aged over 18 years, including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), were enrolled. All eligible patients underwent echocardiography for evaluation of the probability of PH in line with the 2015 European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Guidelines. Sixty-six patients with a median age of 59 years were enrolled. There were 35 PV, 25 ET, and 6 PMF patients included. The prevalence of high echocardiographic probability of PH was 4.55% (2 ET and 1 PMF). Risk factors associated with high echocardiographic probability of PHT were not analyzed. There were three risk factors associated with increased TRVmax, specifically lower hemoglobin, older age, and the presence of JAK2V617F mutation. The prevalence of high echocardiographic probability of PH in MPNs patients was 4.55%.
Keyphrases
- ejection fraction
- end stage renal disease
- risk factors
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- heart failure
- prognostic factors
- computed tomography
- coronary artery
- aortic stenosis
- mitral valve
- coronary artery disease
- physical activity
- aortic valve
- pulmonary artery
- atrial fibrillation
- respiratory tract